Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 68

1.

Rapid single B cell antibody discovery using nanopens and structured light.

Winters A, McFadden K, Bergen J, Landas J, Berry KA, Gonzalez A, Salimi-Moosavi H, Murawsky CM, Tagari P, King CT.

MAbs. 2019 Aug/Sep;11(6):1025-1035. doi: 10.1080/19420862.2019.1624126. Epub 2019 Jun 11.

2.

Nanoscale integration of single cell biologics discovery processes using optofluidic manipulation and monitoring.

Jorgolli M, Nevill T, Winters A, Chen I, Chong S, Lin FF, Mock M, Chen C, Le K, Tan C, Jess P, Xu H, Hamburger A, Stevens J, Munro T, Wu M, Tagari P, Miranda LP.

Biotechnol Bioeng. 2019 Sep;116(9):2393-2411. doi: 10.1002/bit.27024. Epub 2019 Jun 24. Review.

3.

Structure-guided Discovery of Dual-recognition Chemibodies.

Cheng AC, Doherty EM, Johnstone S, DiMauro EF, Dao J, Luthra A, Ye J, Tang J, Nixey T, Min X, Tagari P, Miranda LP, Wang Z.

Sci Rep. 2018 May 15;8(1):7570. doi: 10.1038/s41598-018-25848-0.

4.

Characterization of the direct interaction between KcsA-Kv1.3 and its inhibitors.

Xu H, Hill JJ, Michelsen K, Yamane H, Kurzeja RJ, Tam T, Isaacs RJ, Shen F, Tagari P.

Biochim Biophys Acta. 2015 Oct;1848(10 Pt A):1974-80. doi: 10.1016/j.bbamem.2015.06.011. Epub 2015 Jun 12.

5.

Does epidural morphine loading in addition to thoracic epidural analgesia benefit the postoperative management of morbidly obese patients undergoing open bariatric surgery? A pilot study.

Zotou A, Siampalioti A, Tagari P, Paridis L, Kalfarentzos F, Filos KS.

Obes Surg. 2014 Dec;24(12):2099-108. doi: 10.1007/s11695-014-1305-z.

PMID:
24913242
6.

Epitope discovery for a synthetic polymer nanoparticle: a new strategy for developing a peptide tag.

Yoshimatsu K, Yamazaki T, Hoshino Y, Rose PE, Epstein LF, Miranda LP, Tagari P, Beierle JM, Yonamine Y, Shea KJ.

J Am Chem Soc. 2014 Jan 29;136(4):1194-7. doi: 10.1021/ja410817p. Epub 2014 Jan 16.

7.

Kinetic characterization and identification of a novel inhibitor of hypoxia-inducible factor prolyl hydroxylase 2 using a time-resolved fluorescence resonance energy transfer-based assay technology.

Dao JH, Kurzeja RJ, Morachis JM, Veith H, Lewis J, Yu V, Tegley CM, Tagari P.

Anal Biochem. 2009 Jan 15;384(2):213-23. doi: 10.1016/j.ab.2008.09.052. Epub 2008 Oct 14.

PMID:
18952043
8.

Discovery of novel hydroxy-thiazoles as HIF-alpha prolyl hydroxylase inhibitors: SAR, synthesis, and modeling evaluation.

Tegley CM, Viswanadhan VN, Biswas K, Frohn MJ, Peterkin TA, Chang C, Bürli RW, Dao JH, Veith H, Rogers N, Yoder SC, Biddlecome G, Tagari P, Allen JR, Hungate RW.

Bioorg Med Chem Lett. 2008 Jul 15;18(14):3925-8. doi: 10.1016/j.bmcl.2008.06.031. Epub 2008 Jun 13.

PMID:
18579373
9.

Substituted 2,2-bisaryl-bicycloheptanes as novel and potent inhibitors of 5-lipoxygenase activating protein.

Macdonald D, Brideau C, Chan CC, Falgueyret JP, Frenette R, Guay J, Hutchinson JH, Perrier H, Prasit P, Riendeau D, Tagari P, Thérien M, Young RN, Girard Y.

Bioorg Med Chem Lett. 2008 Mar 15;18(6):2023-7. doi: 10.1016/j.bmcl.2008.01.105. Epub 2008 Feb 2.

PMID:
18276139
10.

New 'chemical probes' to examine the role of the hFPRL1 (or ALXR) receptor in inflammation.

Frohn M, Xu H, Zou X, Chang C, McElvaine M, Plant MH, Wong M, Tagari P, Hungate R, Bürli RW.

Bioorg Med Chem Lett. 2007 Dec 1;17(23):6633-7. Epub 2007 Sep 15.

PMID:
17920884
11.

Potent hFPRL1 (ALXR) agonists as potential anti-inflammatory agents.

Bürli RW, Xu H, Zou X, Muller K, Golden J, Frohn M, Adlam M, Plant MH, Wong M, McElvain M, Regal K, Viswanadhan VN, Tagari P, Hungate R.

Bioorg Med Chem Lett. 2006 Jul 15;16(14):3713-8. Epub 2006 May 11.

PMID:
16697190
12.

Substituted coumarins as potent 5-lipoxygenase inhibitors.

Grimm EL, Brideau C, Chauret N, Chan CC, Delorme D, Ducharme Y, Ethier D, Falgueyret JP, Friesen RW, Guay J, Hamel P, Riendeau D, Soucy-Breau C, Tagari P, Girard Y.

Bioorg Med Chem Lett. 2006 May 1;16(9):2528-31. Epub 2006 Feb 7.

PMID:
16464579
13.

(4-Piperidinylphenyl)aminoethyl amides as a novel class of non-covalent cathepsin K inhibitors.

Kim TS, Hague AB, Lee TI, Lian B, Tegley CM, Wang X, Burgess TL, Qian YX, Ross S, Tagari P, Lin CH, Mayeda C, Dao J, Jordan S, Mohr C, Cheetham J, Viswanadhan V, Tasker AS.

Bioorg Med Chem Lett. 2004 Jan 5;14(1):87-90.

PMID:
14684304
14.

Effects of COX-2 inhibitors on aortic prostacyclin production in cholesterol-fed rabbits.

Wong E, Huang JQ, Tagari P, Riendeau D.

Atherosclerosis. 2001 Aug;157(2):393-402.

PMID:
11472739
15.

Substituted indoles as potent and orally active 5-lipoxygenase activating protein (FLAP) inhibitors.

Frenette R, Hutchinson JH, Léger S, Thérien M, Brideau C, Chan CC, Charleson S, Ethier D, Guay J, Jones TR, McAuliffe M, Piechuta H, Riendeau D, Tagari P, Girard Y.

Bioorg Med Chem Lett. 1999 Aug 16;9(16):2391-6.

PMID:
10476875
16.

Quinolines as potent 5-lipoxygenase inhibitors: synthesis and biological profile of L-746,530.

Dubé D, Blouin M, Brideau C, Chan CC, Desmarais S, Ethier D, Falgueyret JP, Friesen RW, Girard M, Girard Y, Guay J, Riendeau D, Tagari P, Young RN.

Bioorg Med Chem Lett. 1998 May 19;8(10):1255-60.

PMID:
9871745
17.

Analysis of prostaglandin G/H synthase-2 inhibition using peroxidase-induced luminol luminescence.

Forghani F, Ouellet M, Keen S, Percival MD, Tagari P.

Anal Biochem. 1998 Nov 15;264(2):216-21.

PMID:
9866686
18.

Substituted (pyridylmethoxy)naphthalenes as potent and orally active 5-lipoxygenase inhibitors; synthesis, biological profile, and pharmacokinetics of L-739,010.

Hamel P, Riendeau D, Brideau C, Chan CC, Desmarais S, Delorme D, Dubé D, Ducharme Y, Ethier D, Grimm E, Falgueyret JP, Guay J, Jones TR, Kwong E, McAuliffe M, McFarlane CS, Piechuta H, Roumi M, Tagari P, Young RN, Girard Y.

J Med Chem. 1997 Aug 29;40(18):2866-75.

PMID:
9288168
19.

From indomethacin to a selective COX-2 inhibitor. Development of indolalkanoic acids as potent and selective cyclooxygenase-2 inhibitors.

Lau CK, Black WC, Belley M, Chan C, Charleson S, Denis D, Gauthier JY, Gordon R, Guay D, Hamel P, Kargman S, Leblanc Y, Mancini J, Ouellet M, Percival D, Prasit P, Roy P, Skorey K, Tagari P, Vickers P, Wong E.

Adv Exp Med Biol. 1997;407:73-8. No abstract available.

PMID:
9321934
20.

Mechanism of selective inhibition of human prostaglandin G/H synthase-1 and -2 in intact cells.

Kargman S, Wong E, Greig GM, Falgueyret JP, Cromlish W, Ethier D, Yergey JA, Riendeau D, Evans JF, Kennedy B, Tagari P, Francis DA, O'Neill GP.

Biochem Pharmacol. 1996 Oct 11;52(7):1113-25.

PMID:
8831731
21.

Eicosanoids modulate hyperpnea-induced bronchoconstriction in canine peripheral airways.

Omori C, Tagari P, Freed AN.

J Appl Physiol (1985). 1996 Sep;81(3):1255-63.

PMID:
8889761
22.

Epitope-labeled soluble human interleukin-5 (IL-5) receptors. Affinity cross-link labeling, IL-5 binding, and biological activity.

Brown PM, Tagari P, Rowan KR, Yu VL, O'Neill GP, Middaugh CR, Sanyal G, Ford-Hutchinson AW, Nicholson DW.

J Biol Chem. 1995 Dec 8;270(49):29236-43.

23.

Levels of peptidoleukotriene E4 are elevated in active Crohn's disease.

Kim JH, Tagari P, Griffiths AM, Ford-Hutchinson A, Smith C, Sherman PM.

J Pediatr Gastroenterol Nutr. 1995 May;20(4):403-7.

PMID:
7636682
24.

Effect of altitude on urinary leukotriene (LT) E4 excretion and airway responsiveness to histamine in children with atopic asthma.

Christie PE, Yntema JL, Tagari P, Ysselstijn H, Ford-Hutchinson AW, Lee TH.

Eur Respir J. 1995 Mar;8(3):357-63.

25.

Antiasthmatic effects of a leukotriene biosynthesis inhibitor (MK-0591) in allergic dogs.

Becker AB, Black C, Lilley MK, Bajwa K, Ford-Hutchinson AW, Simons FE, Tagari P.

J Appl Physiol (1985). 1995 Feb;78(2):615-22.

PMID:
7759431
26.

A single-step purification of biologically active recombinant human interleukin-5 from a baculovirus expression system.

Brown PM, Scheid MP, O'Neill GP, Tagari PC, Nicholson DW.

Protein Expr Purif. 1995 Feb;6(1):63-71.

PMID:
7756840
27.

Increased urinary LTE4 excretion following inhalation of LTC4 and LTE4 in asthmatic subjects.

Christie PE, Tagari P, Ford-Hutchinson AW, Black C, Markendorf A, Schmitz-Schumann M, Lee TH.

Eur Respir J. 1994 May;7(5):907-13.

28.

Effect of FLAP antagonist MK-0591 on leukotriene production and ozone-induced airway responses in dogs.

Stevens WH, Lane CG, Woolley MJ, Ellis R, Tagari P, Black C, Ford-Hutchinson A, O'Byrne PM.

J Appl Physiol (1985). 1994 Apr;76(4):1583-8.

PMID:
8045835
29.

Measurement of canine urinary thromboxanes by GC-MS and HPLC-RIA.

Tagari P, Callaghan DH, Black C, Yerge JA.

Prostaglandins. 1994 Apr;47(4):293-306.

PMID:
8041872
30.

Chronic leukotriene inhibition in the rat fails to modify the toxicological effects of a cyclooxygenase inhibitor.

Ford-Hutchinson AW, Tagari P, Ching SV, Anderson CA, Coleman JB, Peter CP.

Can J Physiol Pharmacol. 1993 Oct-Nov;71(10-11):806-10.

PMID:
8143238
31.

Assessment of the in vivo biochemical efficacy of orally active leukotriene biosynthesis inhibitors.

Tagari P, Brideau C, Chan C, Frenette R, Black C, Ford-Hutchinson A.

Agents Actions. 1993 Sep;40(1-2):62-71.

PMID:
8147271
32.

A rapid biochemical method for measuring antigen-induced pulmonary eosinophil margination in allergic guinea pigs.

Tagari P, Black C, Marshall S, Ford-Hutchinson AW.

J Immunol Methods. 1993 Jul 6;163(1):49-58.

PMID:
8335959
33.

Leukotriene generation and metabolism in dogs: inhibition of biosynthesis by MK-0591.

Tagari P, Becker A, Brideau C, Frenette R, Sadl V, Thomas E, Vickers P, Ford-Hutchinson A.

J Pharmacol Exp Ther. 1993 Apr;265(1):416-25.

PMID:
8386242
34.

Activation of human eosinophils and differentiated HL-60 cells by interleukin-5.

Tagari P, Pecheur EI, Scheid M, Brown P, Ford-Hutchinson AW, Nicholson D.

Int Arch Allergy Immunol. 1993;101(3):227-33.

PMID:
8391887
35.

Urinary LTE4 excretion in antigen-provoked asthmatic patients treated with the inhaled LTD4 antagonist, L-648,051.

Rasmussen JB, Eriksson LO, Tagari P, Margolskee DJ, Girard Y, Andersson KE.

Allergy. 1992 Dec;47(6):599-603.

PMID:
1337423
36.

Urinary leukotriene E4 after lysine-aspirin inhalation in asthmatic subjects.

Christie PE, Tagari P, Ford-Hutchinson AW, Black C, Markendorf A, Schmitz-Schumann M, Lee TH.

Am Rev Respir Dis. 1992 Dec;146(6):1531-4.

PMID:
1333741
38.

Quantitation of eosinophil Major Basic Protein cytotoxicity to rodent respiratory epithelium.

Tagari P, Chee P, Chan C, McKee K, Black C, Nicholson D, Ford-Hutchinson AW.

Agents Actions. 1992 Nov;37(3-4):171-3.

PMID:
1295362
39.

Leukotriene D4 receptor blockade inhibits the immediate and late bronchoconstrictor responses to inhaled antigen in patients with asthma.

Rasmussen JB, Eriksson LO, Margolskee DJ, Tagari P, Williams VC, Andersson KE.

J Allergy Clin Immunol. 1992 Aug;90(2):193-201.

PMID:
1323587
40.

Increased urinary leukotriene excretion in patients with cardiac ischemia. In vivo evidence for 5-lipoxygenase activation.

Carry M, Korley V, Willerson JT, Weigelt L, Ford-Hutchinson AW, Tagari P.

Circulation. 1992 Jan;85(1):230-6.

PMID:
1309444
41.

Persistent generation of peptido leukotrienes in patients with the adult respiratory distress syndrome.

Bernard GR, Korley V, Chee P, Swindell B, Ford-Hutchinson AW, Tagari P.

Am Rev Respir Dis. 1991 Aug;144(2):263-7.

PMID:
1650152
42.

Urinary leukotriene E4 concentrations increase after aspirin challenge in aspirin-sensitive asthmatic subjects.

Christie PE, Tagari P, Ford-Hutchinson AW, Charlesson S, Chee P, Arm JP, Lee TH.

Am Rev Respir Dis. 1991 May;143(5 Pt 1):1025-9.

PMID:
1850964
43.

Eosinophil-eicosanoid interactions: inhibition of eosinophil chemotaxis in vivo by a LTD4-receptor antagonist.

Chan CC, McKee K, Tagari P, Chee P, Ford-Hutchinson A.

Eur J Pharmacol. 1990 Dec 4;191(3):273-80.

PMID:
1964905
44.

BIO-Fully Automated Sample Treatment high-performance liquid chromatography and radioimmunoassay for leukotriene E4 in human urine from asthmatics.

Nicoll-Griffith D, Zamboni R, Rasmussen JB, Ethier D, Charleson S, Tagari P.

J Chromatogr. 1990 Apr 6;526(2):341-54.

PMID:
2163406
45.

Increased leukotriene E4 excretion during antigen-induced bronchoconstriction in allergic sheep.

Tagari P, Abraham WM, McGolrick J, Charleson S, Soler M, Ahmed A, Cortez A, Ford-Hutchinson AW.

J Appl Physiol (1985). 1990 Apr;68(4):1321-7.

PMID:
2161409
46.

Application of reversed phase high performance liquid chromatography to the analysis of sulphidopeptide leukotrienes in pig bile.

Tagari P, Ethier D, Ford-Hutchinson A, Cirino M.

Biomed Chromatogr. 1990 Jan;4(1):39-42.

PMID:
2310841
47.

Comparison of urinary leukotriene E4 and 16-carboxytetranordihydro leukotriene E4 excretion in allergic asthmatics after inhaled antigen.

Tagari P, Rasmussen JB, Delorme D, Girard Y, Eriksson LO, Charleson S, Ford-Hutchinson AW.

Eicosanoids. 1990;3(2):75-80.

PMID:
2169776
48.

Metabolism and excretion of exogenous [3H]-LTC4 in primates.

Tagari P, Foster A, Delorme D, Girard Y, Rokach J.

Prostaglandins. 1989 Jun;37(6):629-40.

PMID:
2549573
50.

Measurement of urinary leukotrienes by reversed-phase liquid chromatography and radioimmunoassay.

Tagari P, Ethier D, Carry M, Korley V, Charleson S, Girard Y, Zamboni R.

Clin Chem. 1989 Mar;35(3):388-91.

Supplemental Content

Loading ...
Support Center